Modeling of experts’ divergent prior beliefs for a sequential phase III clinical trial
暂无分享,去创建一个
Sarah Zohar | Sylvie Chevret | Philippe Moreau | S. Chevret | J. Mary | P. Moreau | S. Zohar | T. Facon | Jean-Yves Mary | Thierry Facon | M. Moatti | Marion Moatti
[1] K. Hess,et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.
[2] D J Spiegelhalter,et al. The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. , 1994, Statistics in medicine.
[3] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[4] Pierpaolo Brutti,et al. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials. , 2009, Statistics in medicine.
[5] D. Schoenfeld,et al. Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.
[6] B. Freedman. Equipoise and the ethics of clinical research. , 1987, The New England journal of medicine.
[7] P Armitage,et al. Comparison of Bayesian with group sequential methods for monitoring clinical trials. , 1991, Controlled clinical trials.
[8] P M Fayers,et al. Tutorial in biostatistics Bayesian data monitoring in clinical trials. , 1997, Statistics in medicine.
[9] Sindhu R Johnson,et al. Methods to elicit beliefs for Bayesian priors: a systematic review. , 2010, Journal of clinical epidemiology.
[10] B. Pégourié,et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.
[11] W. Satariano,et al. A comparison of two worlds: How does Bayes hold up to the status quo for the analysis of clinical trials? , 2011, Contemporary clinical trials.
[12] Brian J Smith,et al. Adaptive group sequential design for phase II clinical trials: A Bayesian decision theoretic approach , 2009, Statistics in medicine.
[13] Liwen Liang,et al. On Simulation Methods for Two Component Normal Mixture Models under Bayesian Approach , 2009 .
[14] D. Rubin,et al. Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .
[15] José G. Dias,et al. An empirical comparison of EM, SEM and MCMC performance for problematic Gaussian mixture likelihoods , 2004, Stat. Comput..
[16] D. Spiegelhalter,et al. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. , 2003, BJOG : an international journal of obstetrics and gynaecology.
[17] D. Spiegelhalter,et al. Monitoring of large randomised clinical trials: a new approach with Bayesian methods , 2001, The Lancet.
[18] Byron J Gajewski,et al. Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors , 2006, Statistics in medicine.
[19] D. Cox,et al. Analysis of Survival Data. , 1986 .
[20] Geoffrey J. McLachlan,et al. Finite Mixture Models , 2019, Annual Review of Statistics and Its Application.
[21] D. Berry,et al. Interim analyses in clinical trials: classical vs. Bayesian approaches. , 1985, Statistics in medicine.
[22] H. Cohen,et al. Adjuvant chemotherapy in older women with early-stage breast cancer. , 2009, The New England journal of medicine.
[23] Nikos A. Vlassis,et al. A kurtosis-based dynamic approach to Gaussian mixture modeling , 1999, IEEE Trans. Syst. Man Cybern. Part A.
[24] Arnost Komárek,et al. A new R package for Bayesian estimation of multivariate normal mixtures allowing for selection of the number of components and interval-censored data , 2009, Comput. Stat. Data Anal..
[25] D. Berry,et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Lavori,et al. Sequential causal inference: Application to randomized trials of adaptive treatment strategies , 2008, Statistics in medicine.
[27] David Machin,et al. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. , 2003, Controlled clinical trials.
[28] James O. Berger,et al. Why should clinicians care about Bayesian methods , 2001 .
[29] Anastasios A. Tsiatis,et al. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time , 1981 .
[30] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[31] D J Spiegelhalter,et al. The what, why and how of Bayesian clinical trials monitoring. , 1994, Statistics in medicine.
[32] B Fisher,et al. Early stopping of a clinical trial when there is evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. , 1998, Controlled clinical trials.
[33] Mark L. Greenberg,et al. A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design , 2006, Supportive Care in Cancer.
[34] David R. Jones,et al. Bayesian methods in health technology assessment: a review. , 2000, Health technology assessment.
[35] P. Thall,et al. A possible association between aprotinin and improved survival after radical surgery for mesothelioma , 2009, Cancer.
[36] Sylvie Chevret,et al. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. , 2009, Journal of clinical epidemiology.
[37] D.,et al. Regression Models and Life-Tables , 2022 .
[38] Anthony O'Hagan,et al. Probabilistic uncertainty specification: Overview, elaboration techniques and their application to a mechanistic model of carbon flux , 2012, Environ. Model. Softw..
[39] Christian Genest,et al. Combining Probability Distributions: A Critique and an Annotated Bibliography , 1986 .
[40] D. Schoenfeld. The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .
[41] David J. Spiegelhalter,et al. Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.